Pendke Sudhir, Bhalgat Sanchit
Depatrment of Ophthalmology, Indira Gandhi Government Medical College, Nagpur, Maharashtra, India.
Oman J Ophthalmol. 2018 Jan-Apr;11(1):16-20. doi: 10.4103/ojo.OJO_192_2015.
Analysis of safety and efficacy of self-engineered polymethylmethacrylate (Acry C) implants in nonpenetrating glaucoma surgery (NPGS) for control and maintenance of intraocular pressure (IOP) in primary open angle glaucoma (POAG) patients.
This was a hospital-based randomized study. Fifty eyes of 50 POAG patients were divided into 3 groups based on preoperative IOP range. NPGS was done with polymethylmethacrylate implants made from haptics of intraocular lenses. All patients were followed up after 1 day, 1 week, 1 month, 3 months, 6 months, and 12 months. Preoperative IOP range was from 25.62 ± 1.72 to 41.66 ± 1.15 mmHg. Postoperative success was defined as IOP <21 mmHg at 1 month in the absence of additional antiglaucoma medication or other treatment.
A significant reduction in IOP was observed postsurgery in all three groups, changing from a preoperative mean of 25.62 ± 1.72 mmHg, 34.38 ± 2.27 mmHg, and 41.66 ± 1.15 mmHg to a postoperative mean of 13.27 ± 2.13 mmHg, 16.50 ± 2.74 mmHg, and 17.66 ± 1.52 mmHg, respectively ( < 0.001) at 12 months. No significant difference was seen with change in position of the implant, i.e., convexity facing limbus or fornix. No intraoperative complications were observed. The main postoperative complication was failure of filtration in 1 case (3.44%) from Group 1, 5 cases (27.78%) from Group 2, and all 3 cases (100%) from Group 3 at 1 month postoperatively. Thus, 9 eyes (41%) required postoperative antiglaucoma medications following which the IOP was controlled.
NPGS with Acry-C implants is a safe and cost-effective (<1 US dollar) procedure for control of IOP in POAG patients especially those with moderately elevated IOPs.
分析自制聚甲基丙烯酸甲酯(Acry C)植入物在非穿透性青光眼手术(NPGS)中用于控制和维持原发性开角型青光眼(POAG)患者眼压的安全性和有效性。
这是一项基于医院的随机研究。50例POAG患者的50只眼根据术前眼压范围分为3组。使用由人工晶状体襻制成的聚甲基丙烯酸甲酯植入物进行NPGS。所有患者在术后1天、1周、1个月、3个月、6个月和12个月进行随访。术前眼压范围为25.62±1.72至41.66±1.15 mmHg。术后成功定义为术后1个月眼压<21 mmHg,且未使用其他抗青光眼药物或进行其他治疗。
所有三组术后眼压均显著降低,术前平均眼压分别为25.62±1.72 mmHg、34.38±2.27 mmHg和41.66±1.15 mmHg,术后12个月平均眼压分别变为13.27±2.13 mmHg、16.50±2.74 mmHg和17.66±1.52 mmHg(<0.001)。植入物位置改变(即凸面朝向角膜缘或穹窿)无显著差异。未观察到术中并发症。主要术后并发症为术后1个月时,第1组1例(3.44%)、第2组5例(27.78%)和第3组3例(100%)出现滤过失败。因此,9只眼(41%)术后需要使用抗青光眼药物,之后眼压得到控制。
对于POAG患者尤其是眼压中度升高的患者,使用Acry-C植入物的NPGS是一种安全且经济有效的(<1美元)控制眼压的方法。